ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

In Brief: Broder Invokes Cancer Act Provision To Inform Hammer, Bush Of Potential Damage Of 32% Cut

September 7, 1990

Herceptin Regimen Minus Adriamycin Increases Survival With Less Toxicity

October 28, 2011

Cancer Control, Smoking Programs Reorganized

December 7, 1990

Blacks Half As Likely To Get Surgery For Esophageal Cancer

January 28, 2005

Abstracts Of Papers From Gynecologic Oncology Conference

October 10, 1975

ACCC Asks More Community Representation, Clear Separation From Centers In New NCI Division

June 29, 1979